APA (7th ed.) Citation

M, S., F, G., A, S., H, C., V, B., C, M., . . . JB, A. (2024). Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France. OncoTargets and therapy, 17, 439. https://doi.org/10.2147/OTT.S448909

Chicago Style (17th ed.) Citation

M, Sanchis-Borja, Guisier F, Swalduz A, Curcio H, Basse V, Maritaz C, Chouaid C, and Auliac JB. "Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France." OncoTargets and Therapy 17 (2024): 439. https://doi.org/10.2147/OTT.S448909.

MLA (9th ed.) Citation

M, Sanchis-Borja, et al. "Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France." OncoTargets and Therapy, vol. 17, 2024, p. 439, https://doi.org/10.2147/OTT.S448909.